Are you overseeing or involved in COVID-19 clinical trials? Are you starting or conducting a…
Infinity BiologiX (“IBX”), a leader in analytics, bioprocessing and biobanking, announced that the RT-PCR assay performed to detected SARS-CoV-2 in samples from individuals suspected of COVID-19 can detect the Omicron variant.
Since March 2020 IBX has tested over 9 million samples for COVID-19 with an assay using an RT-PCR test that has been confirmed to detect the Omicron variant.
“We’re proud to be providing robust COVID-19 testing as part of our ongoing support for the US response to the COVID-19 pandemic. The ability to detect the Omicron variant using our existing RT-PCR based assay, which targets 3 separate areas of the viral genome, demonstrates our rigorous approach to testing and our commitment to public health.” Robin Grimwood, CEO at IBX.
In addition, IBX has been working with the Centers for Disease Control and Prevention (CDC) to sequence the SARS-CoV-2 genome from positive COVID-19 samples across the United States. The contract “Genomic Surveillance for SARS-COV-2 Variants” aims to provide genomic sequencing and new variant detection of samples of SARS-COV-2 to enable public health officials to investigate the impact of variants on disease severity as well as the effectiveness of vaccines and treatment.
As part of this work with the CDC, IBX have sequenced over 61,000 COVID-19 samples and continue to provide valuable epidemiological data on the spread of novel COVID-19 strains. This sequencing has been performed in the IBX headquarters in NJ (Piscataway).
For more information talk to our team here: https://ibx.bio/contact/